149 related articles for article (PubMed ID: 37704501)
1. Variant allele frequency: a decision-making tool in precision oncology?
Boscolo Bielo L; Trapani D; Repetto M; Crimini E; Valenza C; Belli C; Criscitiello C; Marra A; Subbiah V; Curigliano G
Trends Cancer; 2023 Dec; 9(12):1058-1068. PubMed ID: 37704501
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatics workflows for clinical applications in precision oncology.
Jäger N
Semin Cancer Biol; 2022 Sep; 84():103-112. PubMed ID: 33476720
[TBL] [Abstract][Full Text] [Related]
3. Driver Mutation Variant Allele Frequency in Circulating Tumor DNA and Association with Clinical Outcome in Patients with Non-Small Cell Lung Cancer and EGFR- and KRAS-Mutated Tumors.
Li M; Yang L; Hughes J; van den Hout A; Burns C; Woodhouse R; Dennis L; Hegde P; Oxnard GR; Vietz C
J Mol Diagn; 2022 May; 24(5):543-553. PubMed ID: 35301118
[TBL] [Abstract][Full Text] [Related]
4. Low TP53 variant allele frequency as a biomarker for anti-programmed death (ligand) 1 monotherapy in lung adenocarcinoma.
Wang S; Xie T; Li Y; Guo L; Ying J; Wang Y; Hao X; Wang X; Li J; Xing P
Cancer; 2023 Dec; 129(24):3873-3883. PubMed ID: 37538036
[TBL] [Abstract][Full Text] [Related]
5. Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions.
Gong B; Li D; Kusko R; Novoradovskaya N; Zhang Y; Wang S; Pabón-Peña C; Zhang Z; Lai K; Cai W; LoCoco JS; Lader E; Richmond TA; Mittal VK; Liu LC; Johann DJ; Willey JC; Bushel PR; Yu Y; Xu C; Chen G; Burgess D; Cawley S; Giorda K; Haseley N; Qiu F; Wilkins K; Arib H; Attwooll C; Babson K; Bao L; Bao W; Lucas AB; Best H; Bhandari A; Bisgin H; Blackburn J; Blomquist TM; Boardman L; Burgher B; Butler DJ; Chang CJ; Chaubey A; Chen T; Chierici M; Chin CR; Close D; Conroy J; Cooley Coleman J; Craig DJ; Crawford E; Del Pozo A; Deveson IW; Duncan D; Eterovic AK; Fan X; Foox J; Furlanello C; Ghosal A; Glenn S; Guan M; Haag C; Hang X; Happe S; Hennigan B; Hipp J; Hong H; Horvath K; Hu J; Hung LY; Jarosz M; Kerkhof J; Kipp B; Kreil DP; Łabaj P; Lapunzina P; Li P; Li QZ; Li W; Li Z; Liang Y; Liu S; Liu Z; Ma C; Marella N; Martín-Arenas R; Megherbi DB; Meng Q; Mieczkowski PA; Morrison T; Muzny D; Ning B; Parsons BL; Paweletz CP; Pirooznia M; Qu W; Raymond A; Rindler P; Ringler R; Sadikovic B; Scherer A; Schulze E; Sebra R; Shaknovich R; Shi Q; Shi T; Silla-Castro JC; Smith M; López MS; Song P; Stetson D; Strahl M; Stuart A; Supplee J; Szankasi P; Tan H; Tang LY; Tao Y; Thakkar S; Thierry-Mieg D; Thierry-Mieg J; Thodima VJ; Thomas D; Tichý B; Tom N; Garcia EV; Verma S; Walker K; Wang C; Wang J; Wang Y; Wen Z; Wirta V; Wu L; Xiao C; Xiao W; Xu S; Yang M; Ying J; Yip SH; Zhang G; Zhang S; Zhao M; Zheng Y; Zhou X; Mason CE; Mercer T; Tong W; Shi L; Jones W; Xu J
Genome Biol; 2021 Apr; 22(1):109. PubMed ID: 33863344
[TBL] [Abstract][Full Text] [Related]
6. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
7. Variant Interpretation for Cancer (VIC): a computational tool for assessing clinical impacts of somatic variants.
He MM; Li Q; Yan M; Cao H; Hu Y; He KY; Cao K; Li MM; Wang K
Genome Med; 2019 Aug; 11(1):53. PubMed ID: 31443733
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and detection of low-allele-fraction variants in clinical cancer samples.
Shin HT; Choi YL; Yun JW; Kim NKD; Kim SY; Jeon HJ; Nam JY; Lee C; Ryu D; Kim SC; Park K; Lee E; Bae JS; Son DS; Joung JG; Lee J; Kim ST; Ahn MJ; Lee SH; Ahn JS; Lee WY; Oh BY; Park YH; Lee JE; Lee KH; Kim HC; Kim KM; Im YH; Park K; Park PJ; Park WY
Nat Commun; 2017 Nov; 8(1):1377. PubMed ID: 29123093
[TBL] [Abstract][Full Text] [Related]
9. Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients.
Galant N; Nicoś M; Kuźnar-Kamińska B; Krawczyk P
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398173
[TBL] [Abstract][Full Text] [Related]
10. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
11. The prognostic impact of variant allele frequency (VAF) in TP53 mutant patients with MDS: A systematic review and meta-analysis.
Deng J; Wu X; Ling Y; Liu X; Zheng X; Ye W; Gong Y
Eur J Haematol; 2020 Nov; 105(5):524-539. PubMed ID: 32621334
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy.
Khotskaya YB; Mills GB; Mills Shaw KR
Annu Rev Med; 2017 Jan; 68():113-125. PubMed ID: 27813876
[TBL] [Abstract][Full Text] [Related]
13. Genetic and genomic learning needs of oncologists and oncology nurses in the era of precision medicine: a scoping review.
Rahman B; McEwen A; Phillips JL; Tucker K; Goldstein D; Jacobs C
Per Med; 2022 Mar; 19(2):139-153. PubMed ID: 35060769
[TBL] [Abstract][Full Text] [Related]
14. Biomarker testing in cancer management- can one size fit all?
Sholl LM; Halmos B
Br J Cancer; 2022 Oct; 127(7):1177-1179. PubMed ID: 36064588
[TBL] [Abstract][Full Text] [Related]
15. Molecular-based precision oncology clinical decision making augmented by artificial intelligence.
Zeng J; Shufean MA
Emerg Top Life Sci; 2021 Dec; 5(6):757-764. PubMed ID: 34874054
[TBL] [Abstract][Full Text] [Related]
16. Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.
Jobanputra V; Wrzeszczynski KO; Buttner R; Caldas C; Cuppen E; Grimmond S; Haferlach T; Mullighan C; Schuh A; Elemento O
Semin Cancer Biol; 2022 Sep; 84():23-31. PubMed ID: 34256129
[TBL] [Abstract][Full Text] [Related]
17. Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.
Jiang L; Ye L; Ma L; Ren Y; Zhou X; Mei C; Xu G; Yang H; Lu C; Luo Y; Zhu S; Wang L; Shen C; Yang W; Zhang Q; Wang Y; Lang W; Han Y; Jin J; Tong H
J Cancer Res Clin Oncol; 2022 Apr; 148(4):845-856. PubMed ID: 35013795
[TBL] [Abstract][Full Text] [Related]
18. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
19. Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice.
Tsongalis GJ; Coleman WB
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S60-S66. PubMed ID: 28921651
[TBL] [Abstract][Full Text] [Related]
20. Knowledge base toward understanding actionable alterations and realizing precision oncology.
Takeuchi S; Okuda S
Int J Clin Oncol; 2019 Feb; 24(2):123-130. PubMed ID: 30542800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
